Skip to main
IFRX
IFRX logo

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

InflaRx NV has received European Commission marketing authorization for its product vilobelimab (Gohibic) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS), indicating regulatory confidence in its clinical efficacy and safety. The treatment demonstrated a notable 23.9% relative reduction in 28-day all-cause mortality compared to placebo, coupled with a well-tolerated safety profile across various doses. Additionally, forecasts project a strong market performance with projected sales of $86 million in 2030, growing to $225 million by 2031, reflecting a solid revenue trajectory as the company advances its innovative therapies.

Bears say

InflaRx NV has reported a decrease in C5a levels from baseline, indicating some efficacy of its product candidate, vilobelimab; however, the overall clinical outcomes, such as the maximum HiSCR rate of 51.5%, are modest when compared to the placebo's 47.1%. The company is exploring partnerships and distribution options in Europe, which may mitigate cash burn but does not address underlying challenges in achieving competitive clinical results. Consequently, these factors contribute to a cautious outlook regarding the company's financial sustainability and market position moving forward.

InflaRx (IFRX) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 14 analysts, InflaRx (IFRX) has a Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.